Skip to main content
. 2020 Feb 17;93:268–276. doi: 10.1016/j.ijid.2020.02.018

Figure 1.

Figure 1

Discovery of novel activities and follow-up development of broad-spectrum antiviral agents (BSAAs). Yellow shading indicates a process of discovery and development of safe-in-man BSAAs, for which pharmacokinetic (PK) properties in pre-clinical (animal model) and early clinical developmental phases (phase 0-IIa trials) are already available. Abbreviations: ESCs, human embryonic stem cells; iPSCs, human induced pluripotent stem cells (iPSCs).